Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,025 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06715501 | Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | enrolling by invitation | N/A | 20 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER |
| 1 |
| Mar 21, 2025 |
| clinicaltrials |
| NCT05835804 | Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers(NIVOCHIMLOC) | not yet recruiting | Phase 2 | 39 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06879964 | Usefulness of Post-Operative Radiotherapy in High-grade Cutaneous Squamous Cell Carcinoma: an Observational Study(PORTSCC) | recruiting | — | 120 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06869473 | Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.(AVEC-119) | recruiting | Phase 2 | 67 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT04632433 | Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma | active not recruiting | Phase 2 | 25 | Fondazione Melanoma OnlusOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04510129 | A Multicenter Cancer Biospecimen Collection Study | recruiting | — | 1,650 | Cofactor Genomics, Inc.INDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05741073 | Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC | recruiting | — | 1,300 | EuMelaReg gGmbHINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06861777 | Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC | not yet recruiting | Phase 2 / Phase 3 | 474 | YIN LIOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06863831 | A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC | enrolling by invitation | N/A | 536 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04460352 | Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer(NEEDS) | recruiting | Phase 3 | 1,020 | Karolinska University HospitalOTHER | 5 | Mar 6, 2025 | clinicaltrials |
| NCT06861036 | Heterogeneity of Oral Squamous Cell Carcinoma Analysis by Single Cell RNA Sequencing(HOASIS) | not yet recruiting | N/A | 50 | Centre Leon BerardOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06852456 | QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 28, 2025 | clinicaltrials |
| NCT06494943 | Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC | recruiting | Phase 1 / Phase 2 | 27 | Fudan UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT05955924 | Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial(SPRINTR) | recruiting | Phase 3 | 396 | Women's College HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06697964 | High Resolution Anuscopy Study | recruiting | — | 500 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04001543 | Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer(SIMPA01) | active not recruiting | N/A | 27 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06470217 | Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma(OPTimal) | recruiting | Phase 2 | 116 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT04475952 | Early Diagnosis of Upper Digestive Tract Disease(E-DIGEST) | recruiting | — | 180 | Imperial College LondonOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04567056 | Specific Methylation Profiles in HNSCC | recruiting | — | 300 | Aalborg University HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06814067 | Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06815705 | Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma Surgery | not yet recruiting | N/A | 23 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT05451303 | Detection of Oral and Throat Cancers Using OralViome Cancer Testing System | recruiting | — | 475 | ViomeINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06174428 | Validity of Viome's Oral/throat Cancer Test | recruiting | — | 1,000 | ViomeINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04857164 | Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China | recruiting | Phase 2 | 150 | Yuankai ShiOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04050436 | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer(CERPASS) | active not recruiting | Phase 2 | 231 | Replimune, Inc.INDUSTRY | 10 | Jan 27, 2025 | clinicaltrials |
| NCT05202860 | Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis(VAXAK) | active not recruiting | Phase 2 | 70 | Merete HaedersdalOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06489197 | AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | recruiting | Phase 1 / Phase 2 | 71 | ImmunoGenesisINDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06087614 | Dose Escalation Using Hypoxia-adjusted Radiotherapy(DE-HyART) | recruiting | Phase 2 | 124 | Rajiv Gandhi Cancer Institute & Research Center, IndiaOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers(VALUE-CHECK) | recruiting | Phase 2 | 360 | National University Hospital, SingaporeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06762158 | NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC | active not recruiting | N/A | 50 | RenJi HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06759155 | Phase II Clinical Trial of De-Intensified Therapy in Human Papilloma Virus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | University of Vermont Medical CenterOTHER | 0 | Jan 6, 2025 | clinicaltrials |
| NCT06755762 | Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer | recruiting | — | 88 | Chang Gung Memorial HospitalOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05214222 | Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma(ANSWER) | recruiting | Phase 2 | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06749665 | Sclerotherapy and Candida Antigen in Treatment of Common Warts | not yet recruiting | N/A | 75 | Sohag UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746961 | Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy | not yet recruiting | Phase 1 / Phase 2 | 49 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT04719988 | Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.(INTERACT-ION) | active not recruiting | Phase 2 | 55 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05877430 | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 160 | CJ Bioscience, Inc.INDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT06741982 | A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus | recruiting | Phase 1 | 21 | West China HospitalOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06647836 | The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma | enrolling by invitation | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06728618 | Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06725498 | Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC | recruiting | Phase 2 | 50 | Beijing Tongren HospitalOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06726512 | Quantitative Margin Assessment Using High-resolution Positron Emission Tomography - Computed Tomograhy(qMAP) | not yet recruiting | N/A | 30 | University Medical Center GroningenOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06727162 | The Value of CEUS in Assessing the Response of Cervical Lymph Nodes After NACI for HNSCC | recruiting | — | 100 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT04843098 | Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 108 | Suzhou Junde Biotechnology Co., LtdINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06713655 | Predicting Treatment Failure in HSIL Patients with Positive Margins After Conization Via Detection of PAX1 Methylation | not yet recruiting | — | 800 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06719479 | A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.). | not yet recruiting | Phase 2 / Phase 3 | 60 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Dec 5, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 25, 2025source: clinicaltrials